Cyclin-dependent kinases and Glycogen synthase kinase-3 beta; Proteasome subunit beta type-5 (CDKs, GSK-3β, and PSMB5)

This entry represents a composite of three distinct therapeutic target classes: Cyclin-dependent kinases (CDKs), Glycogen synthase kinase-3 beta (GSK-3β), and the Proteasome subunit beta type-5 (PSMB5). CDKs are a family of serine/threonine kinases that regulate the eukaryotic cell cycle and transcription, and their inhibition is a primary strategy in treating various solid tumors (PMID: 25877024). GSK-3β is a multifunctional kinase involved in the Wnt/beta-catenin and insulin signaling pathways, playing critical roles in neurodevelopment and metabolism, making it a target for Alzheimer's disease and psychiatric disorders (UniProt P49841). PSMB5 is the essential catalytic subunit of the 20S proteasome core responsible for chymotrypsin-like activity; its inhibition by drugs like bortezomib disrupts protein homeostasis and is a cornerstone of therapy for multiple myeloma (PMID: 15155836). Because these entities represent separate protein families with different biological functions and pharmacological profiles, they are typically classified as individual targets rather than a single unit.

Other names

Cell division protein kinasesGSK3B20S proteasome subunit beta-5PSMB5Chymotrypsin-like protease subunit

Inhibition of cyclin-dependent kinase activity to arrest the cell cycle; inhibition of GSK-3β to modulate Wnt signaling and glucose metabolism; and reversible or irreversible inhibition of the PSMB5 chymotrypsin-like activity to block the ubiquitin-proteasome pathway, leading to the accumulation of misfolded proteins and induction of apoptosis.